MHLW To Review Shionogi’s Idiopathic Pulmonary Fibrosis Drug
This article was originally published in PharmAsia News
Executive Summary
The first section on drugs of the Pharmaceutical Affairs and Food Sanitation Council at the Ministry of Health, Labor and Welfare will review Shionogi's pirfenidone for the treatment of idiopathic pulmonary fibrosis. The Phase III trial conducted this year at Shinagawa Prefecture Cardiovascular and Respiratory Center showed a delay of symptom progression compared to placebo. Designated as an intractable disease in Japan, IPF currently has no thorough treatment. (Click here for more - Japanese language
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.